VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody

Immunohistochemistry Human - MLH1

Experiment
Immunohistochemistry Human - MLH1
Product
VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody from Roche Lifesciences
Manufacturer
Roche Lifesciences

Protocol tips

Publication protocol

The review of hematoxylin and eosin slides were performed by two experienced pathologists (J.S.K. and S.W.H.), and one representative block was selected for each case. Immunohistochemistry was performed on the representative paraffin-embedded 4 μm-thick whole tissue sections using a BenchMark XT automated stainer (Ventana Medical Systems, Tucson, AZ, USA) for CD8 (clone CD/144B, 1:100; Cell Marque, Rocklin, CA, USA), p53 (clone DO-7, 1:3000; Novocastra, Buffalo Grove, IL, USA) and MMR proteins, and a Leica automated stainer (Bond Max) for PD-1 (clone NAT105, 1:100; Cell marque) and PD-L1 (clone E1L3N, 1:150; Cell Signaling, Danvers, MA, USA). Antibodies used for MMR proteins were anti-human MLH1 (clone M1, ready to use; Ventana, Oro Valley, AZ, USA), MSH2 (clone G219-1129, ready to use; Ventana), MSH6 (clone 44, ready to use; Ventana), and PMS2 (clone ERP3947, ready to use; Ventana) monoclonal antibodies. Immunohistochemical evaluation was performed by two experienced pathologists (J.S.K. and S.W.H.) blinded to clinical data. Loss of MMR proteins (MMR deficiency) was defined as a complete loss of nuclear staining in the tumor cells with positive internal controls (stromal cells, lymphocytes, or normal endometrium). CD8 expression was evaluated as the number of CD8+ T lymphocytes in 10 randomly selected high-power fields (HPFs). P53 staining was scored as 0 (completely negative), 1 (focal, weak to moderate positive), and 2 (diffuse > 80%, strong positive); scores of 0 and 2 were regarded as abnormal, and a score of 1 was regarded as normal [39]. PD-1 and PD-L1 expression in immune cells were evaluated as the percentage of PD-1+ or PD-L1+ immune cells relative to the total number of immune cells in tumor stroma. PD-L1 expression in tumor cells was evaluated as the percentage of PD-L1+ tumor cells showing membranous expression relative to total number of tumor cells.

Full paper   Login or join for free to view the full paper.

Reviews

VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody from Roche Lifesciences has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing Immunohistochemistry Human - MLH1 using VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody from Roche Lifesciences.

View full paper   Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Roche Lifesciences for VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody below.

We haven't found the manufacturer protocol for this product yet.

Videos

Check out videos that might be relevant for performing Immunohistochemistry Human - MLH1 using VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody from Roche Lifesciences. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms